Collaboration with Bridge Biotherapeutics

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge BiotherapeuticsBoehringer Ingelheim has entered into a collaboration and global license agreement for Bridge Biotherapeutics ’s autotaxin inhibitor BBT-877 to be developed for fibrosing interstitial lung diseases including IPFWith this new partnership Boehringer Ingelheim further expands its commitment to bring new treatments to patients with fibrosing interstitial lung diseases including IPFBridge Biotherapeutics stands to receive up to more than EUR 1.1 billion assuming all milestones are met  

Source: Boehringer Ingelheim Corporate News - July 18, 2019 Category: Research Source Type: news